Impact of rifampicin addition to clarithromycin in Legionella pneumophila pneumonia

被引:28
作者
Grau, Santiago
Mateu-de Antonio, Javier
Ribes, Esther
Savado, Margarita
Garces, Jose Maria
Garau, Javier
机构
[1] Hosp del Mar, Dept Pharm, Barcelona 08003, Spain
[2] Lab Referencia Catalunya, Barcelona, Spain
[3] Hosp del Mar, Dept Internal Med, Barcelona 08003, Spain
[4] Univ Barcelona, Dept Med, Hosp Mutua de Terrassa, Barcelona, Spain
关键词
drug interactions; Legionnaires' disease; length of stay; liver function tests; rifampicin;
D O I
10.1016/j.ijantimicag.2006.03.029
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
We evaluated the effectiveness and safety of rifampicin addition to clarithromycin in the treatment of Legionnaires' disease. An observational cohort study was conducted on patients assigned to a Legionnaires' disease outbreak. Of 32 patients with confirmed Legionella pneumonia, I I received clarithromycin monotherapy and 21 received combination therapy of clarithromycin with rifampicin. Both groups had similar baseline characteristics and all patients were cured. Patients who received rifampicin had a 50% longer length of stay (P = 0.035) and a trend towards higher bilirubin levels (P = 0.053). Length of stay was directly correlated with the duration of rifampicin treatment (P = 0.001). Combination therapy of clarithromycin and rifampicin had no additional benefit compared with clarithromycin monotherapy and could prolong the length of stay owing to possible negative drug interactions that could also affect other antibiotics. (c) 2006 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:249 / 252
页数:4
相关论文
共 12 条
[1]   Treatment of Legionnaires' disease [J].
Amsden, GW .
DRUGS, 2005, 65 (05) :605-614
[2]  
BACHMANN KA, 2004, DRUG INTERACTIONS HD
[3]  
DOURNON E, 1990, J ANTIMICROB CHEM SB, V26, pS129
[4]  
EDELSTEIN PH, 2005, PRINCIPLES PRACTICE, P2711
[5]  
HUBBARD RB, 1993, Q J MED, V86, P327
[6]   Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults [J].
Mandell, LA ;
Bartlett, JG ;
Dowell, SF ;
File, TM ;
Musher, DM ;
Whitney, C .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (11) :1405-1432
[7]   Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era:: The influence of Levofloxacin therapy [J].
Mykietiuk, A ;
Carratalà, J ;
Fernández-Sabé, N ;
Dorca, J ;
Verdaguer, R ;
Manresa, F ;
Gudiol, F .
CLINICAL INFECTIOUS DISEASES, 2005, 40 (06) :794-799
[8]   Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin [J].
Patel, KB ;
Xuan, DW ;
Tessier, PR ;
Russomanno, JH ;
Quintiliani, R ;
Nightingale, CH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) :2375-2379
[9]  
Peloquin CA, 1996, J INFECT DIS PHARMAC, V2, P19
[10]   Clinical pharmacokinetics of clarithromycin [J].
Rodvold, KA .
CLINICAL PHARMACOKINETICS, 1999, 37 (05) :385-398